Market Place
Sourcing Support
AIM ImmunoTech Wins Japan Patent For Ampligen Combo Therapy
18 Mar 2026 //
GLOBENEWSWIRE
AIM ImmunoTech Signs Ampligen Phase 3 Trial Deal
02 Mar 2026 //
GLOBENEWSWIRE
AIM Reports Positive Interim Ph2 Data of Ampligen Combo in Cancer
05 Feb 2026 //
GLOBENEWSWIRE
AIM Immunotech Announces Release Of The Next CEO Corner Segment
10 Dec 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Reports Q3 2025 Financials on Pancreatic Cancer
18 Nov 2025 //
GLOBENEWSWIRE
AIM Immunotech Reveals UPMC Abstract On Ampligen`s Role
10 Nov 2025 //
GLOBENEWSWIRE
AIM Immunotech To Present Upmc Abstract At SITC Meeting
04 Nov 2025 //
GLOBENEWSWIRE
AIM Immunotech Secures European Patent For Ampligen
03 Nov 2025 //
GLOBENEWSWIRE
Aim Immunotech Reveals Journal Article On Ampligen
22 Sep 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Showcases Ampligen Data in Pancreatic Cancer
04 Sep 2025 //
GLOBENEWSWIRE
Aim Immuno Tech Drives Ampligen Toward Pancreatic Cancer Approval
04 Aug 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Prices $8.0 Million Public Offering
29 Jul 2025 //
GLOBENEWSWIRE
AIM Reports Positive Ph2 Data on Ampligen + Imfinzi in Cancer
28 Jul 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Resumes Trading on NYSE American
17 Jun 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Gets US Patent for dsRNA Manufacturing
12 Jun 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Presents Ampligen Oncology Data at Annual Meeting
08 May 2025 //
GLOBENEWSWIRE
AIM ImmunoTech trades as AIMI on Pink Open Market
07 Apr 2025 //
GLOBENEWSWIRE
AIM Immuno Announces NYSE American Notice of Delisting and Appeal
04 Apr 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Reports Q4 and Full Year 2024 Financial Results
27 Mar 2025 //
GLOBENEWSWIRE
AIM Names Paul Goepfert As PI For Avian Flu Vaccine Study
28 Feb 2025 //
GLOBENEWSWIRE
AIM doses first subject in Phase 2 study of Ampligen and Imfinzi
25 Feb 2025 //
GLOBENEWSWIRE
AIM Plans Study Of Ampligen® & FluMist® For Avian Influenza
07 Feb 2025 //
GLOBENEWSWIRE
Erasmus Safety Committee Approves Ph 2 Study for Pancreatic Cancer
05 Feb 2025 //
GLOBENEWSWIRE
AIM Publishes Final Results On Ampligen For Post-COVID Conditions
23 Jan 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Link Between COVID-19 & ME/CFS In New Article
22 Jan 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Expand Patent Portfolio For Post-COVID Fatigue Drug
12 Dec 2024 //
GLOBENEWSWIRE
Glass Lewis Recommends AIM ImmunoTech Shareholders Vote Nominees
10 Dec 2024 //
BUSINESSWIRE
AIM Immuno Gets US Patent For Ampligen® In Endometriosis Treatment
03 Oct 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Reports Positive Data In Pancreatic Cancer Study
19 Sep 2024 //
GLOBENEWSWIRE
AIM ImmunoTech: Ampligen Shows Promise For Post-COVID Fatigue
11 Sep 2024 //
GLOBENEWSWIRE
AIM ImmunoTech To Discuss Q2 2024 Results On August 16
13 Aug 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Appoints Dr. Lapp As ME/CFS, Long COVID Consultant
15 Apr 2024 //
GLOBENEWSWIRE
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
28 Mar 2024 //
GLOBENEWSWIRE
AIM Announces Translational Data from Phase 2 Study Evaluating Ampligen
08 Nov 2023 //
GLOBENEWSWIRE
